Adamantinoma of long bone (AD) and giant cell tumor of bone (GCTB) typically present as solitary bone lesions. It is extremely rare for both types of tumors to occur simultaneously in one patient. This article reports a 17-year-old female patient who was admitted to the hospital due to right knee pain. Imagery suggested that the lower of the right femur and the upper of the right tibia had undergone bone destruction with the formation of soft tissue shadows. The clinicians diagnosed bone tumors and perform tumor curettage. The postoperative pathological diagnosis of the right femur lesion was GCTB, and the right tibia lesion was AD. The postoperative recovery was favorable, and no recurrence or metastasis so far. In this paper, we review the relevant literatures and summarize the clinical manifestations, imaging characteristics, pathomorphological features, and treatment modalities of GCTB and AD.

1.Smyth SL, Siddiqi A, Athanasou N, et al. Adamantinoma: a review of the current literature[J]. J Bone Oncol, 2023, 41: 100489. DOI: 10.1016/j.jbo.2023.100489.

2.Aoude A, Nikomarov D, Perera JR, et al. Giant cell tumour of bone[J]. Bone Joint J, 2023, 105-B(5): 559-567. DOI: 10.1302/0301-620X.105B5.BJJ-2022-1231.R1.

3.林善平,伍四春. 骶骨巨大骨巨细胞瘤1例[J]. 解放军医学杂志, 2006, 31(4): 369. [Lin SP, Wu SC. A case of giant cell tumour of bone of the Sacrum[J]. Medical Journal of Chinese People's Liberation Army, 2006, 31(4): 369.] DOI: 10.3321/j.issn:0577-7402.2006.04.034.

4.魏剑,徐维邦. 少见原发髌骨骨巨细胞瘤1例[J]. 陆军军医大学学报, 2001, 23(11): 1289. [Wei J, Xu WB. Report a case of osteoclastoma in patella[J]. Journal of Army Medical University, 2001, 23(11): 1289.] DOI: 10.3321/j.issn:1000-5404.2001.11.057.

5.Trovarellt G, Rizzo A, Cerchiaro M, et al. The evaluation and management of lung metastases in patients with giant cell tumors of bone in the denosumab era[J]. Curr Oncol, 2024, 31(4): 2158-2171. DOI: 10.3390/curroncol31040160.

6.Deventer N, Budny T, Gosheger G, et al. Giant cell tumor of bone: a single center study of 115 cases[J]. J Bone Oncol, 2022, 33: 100417. DOI: 10.1016/j.jbo.2022.100417.

7.Parmeggiani A, Micelt M, Errant C, et al. State of the art and new concepts in giant cell tumor of bone: imaging features and tumor characteristics[J]. Cancers (Basel), 2021, 13(24): 6298. DOI: 10.3390/cancers13246298.

8.Jha Y, Chaudhapy K. Giant cell tumour of bone: a comprehensive review of pathogenesis, diagnosis, and treatment[J]. Cureus, 2023, 15(10): e46945. DOI: 10.7759/cureus.46945.

9.Imre A, Zoltán S, Miklós S. Current indications for denosumab in benign bone tumours[J]. EFORT Open Rev, 2023, 8(12): 895-905. DOI: 10.1530/EOR-23-0138.

10.Ratnagirt R, Uppin S. H3F3A mutation as a marker of malignant giant cell tumor of the bone: a case report and review of literature[J]. J Cancer Res Ther, 2023, 19(3): 832-834. DOI: 10.4103/jcrt.jcrt_247_21.

11.Miskad UA, Syamsul F, Dahlan H, et al. Significance of histone H3.3 (G34W)-mutant protein in pathological diagnosis of giant cell tumor of bone[J]. Asian Pac J Cancer Prev, 2023, 24(5): 1737-1741. DOI: 10.31557/APJCP.2023.24.5.1737.

12.张文,宫丽华,丁宜. SATB2是成骨细胞分化的敏感但不特异的标记[J]. 中国组织化学与细胞化学杂志, 2020, 29(2): 137-143. [Zhang W, Gong LH, Ding Y. STAB2 is a sensitive but not specific marker for osteoblastic differentiation[J]. Chinese Journal of Histochemistry and Cytochemistry, 2020, 29(2): 137-143.] DOI: 10.16705/j.cnki.1004-1850.2020.02.006.

13.郑楷. 骨巨细胞瘤中p63、Ki-67的表达及影像学分级与临床病理因素的相关性研究[D]. 广州: 广州医科大学,2021.[ Zheng K. The correlative study of clinical pathological factors between expression of p63 and Ki-67 and radiological grading in giantcell tumor of bone[D]. Guangzhou: Guangzhou Medical University,2021.] https://d.wanfangdata.com.cn/thesis/D02483008

14.Giesche J, Mellert K, Geißler S, et al. Epigenetic lockdown of CDKN1A (p21) and CDKN2A (p16) characterises the neoplastic spindle cell component of giant cell tumours of bone[J]. J Pathol, 2022, 257(5): 687-696. DOI: 10.1002/path.5925.

15.翁海燕,王志华,王晓秋,等. 长骨造釉细胞瘤临床病理分析 [J]. 临床与实验病理学杂志, 2007, 23(2): 186-188. [Weng  HY, Wang ZH, Wang XQ, et al. Adamantinoma of long bone: a clinicopathological study[J]. Chinese Journal of Clinical and Experimental Pathology, 2007, 23(2): 186-188.] DOI: 10.3969/j.issn.1001-7399.2007.02.015.

16.WHO Classification of Tumours Editorial Board. WHO classification of tumours. Soft tissue and bone tumours. 5th Edition[M]. IARC Press: Lyon, 2020: 463-466.

17.Varvarousis DN, Skandalakis GP, Barbouti A, et al. Adamantinoma: an updated review [J]. In Vivo, 2021, 35(6): 3045-3052. DOI: 10.21873/invivo.12600.

18.Bora N, Kashikar SV, Parihar P, et al. Adamantinoma: an uncommon cause of bone pain in a young adolescent male[J]. Cureus, 2023, 15(12): e50214. DOI: 10.7759/cureus.50214.

19.Schutgens EM, Picci P, Baumhoer D, et al. Surgical outcome and oncological survival of osteofibrous dysplasia-like and classic adamantinomas[J]. J Bone Joint Surg Am, 2020, 102(19): 1703-1713. DOI: 10.2106/JBJS.19.01056.

20.Bethapudi S, Ritchie DA, Macduff E, et al. Imaging in osteofibrous dysplasia, osteofibrous dysplasia-like adamantinoma, and classic adamantinoma[J]. Clin Radiol, 2014, 69(2): 200-208. DOI: 10.1016/j.crad.2013.09.011.

21.Gleason BC, Liegl-Atzwanger B, Kozakewich HP, et al. Osteofibrous dysplasia and adamantinoma in children and adolescents: a clinicopathologic reappraisal[J]. Am J Surg Pathol, 2008, 32(3): 363-376. DOI: 10.1097/PAS.0b013e318150d53e.

22.Jain D, Jain VK, Vasishta RK, et al. Adamantinoma: a clinicopathological review and update[J]. Diagn Pathol, 2008, 3: 8. DOI: 10.1186/1746-1596-3-8.

23.Hazelbag HM, Fleuren GJ, vd Broek LJ, et al. Adamantinoma of the long bones: keratin subclass immunoreactivity pattern with reference to its histogenesis[J]. Am J Surg Pathol, 1993, 17(12): 1225-1233. DOI: 10.1097/00000478-199312000-00003.

24.Horvai A, Dashti NK, Rubin BP, et al. Genetic and molecular reappraisal of spindle cell adamantinoma of bone reveals a small subset of misclassified intraosseous synovial sarcoma[J]. Mod Pathol, 2019, 32(2): 231-241. DOI: 10.1038/s41379-018-0115-6.

25.Dickson BC, Gortzak Y, Bell RS, et al. p63 expression in adamantinoma[J]. Virchows Arch, 2011, 459(1): 109-113. DOI: 10.1007/s00428-011-1101-2.

26.莫超华,毛荣军,谢乐,等. 长骨釉质瘤及其去分化亚型临床病理分析[J]. 右江民族医学院学报, 2020, 42(4): 432-436, 441. [Mo CH, Mao RJ, Xie L, et al. Clinicopathological analysis of adamantinoma of long bones and its dedifferentiated subtypes[J]. Journal of Youjiang Medical University for Nationalities, 2020, 42(4): 432-436, 441.] DOI: 10.3969/j.issn.1001-5817.2020.04.007.

27.El Beaino M, Wang WL, Alaraj SF, et al. Osteofibrous dysplasia and adamantinoma: a summary of diagnostic challenges and surgical techniques[J]. Surg Oncol, 2021, 38: 101626. DOI: 10.1016/j.suronc.2021.101626.

28.Houdek MT, Sherman CE, Inwards CY, et al. Adamantinoma of bone: long-term follow-up of 46 consecutive patients[J]. J Surg Oncol, 2018, 118(7): 1150-1154. DOI: 10.1002/jso.25269.

29.Takase H, Kato I, Ito J, et al. Giant cell tumor of bone without giant cells with a long clinical course: a case report[J]. Int J Surg Pathol, 2022, 31(2): 190-194. DOI: 10.1177/10668969221098090.

30.Rooper LM, Bishop JA. Soft tissue special issue: adamantinoma-like ewing sarcoma of the head and neck: a practical review of a challenging emerging entity[J]. Head Neck Pathol, 2020, 14(1): 59-69. DOI: 10.1007/s12105-019-01098-y.

31.Wang QA, Chen HW, Wu RC, et al. Update of diagnosis and targeted therapy for ALK+ inflammation myofibroblastic tumor[J]. Curr Treat Options Oncol, 2023, 24(12): 1683-1702. DOI: 10.1007/s11864-023-01144-6.

32.Blay JY, Von Mehren M, Jones RL, et al. Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies[J]. ESMO Open, 2023, 8(5): 101618. DOI: 10.1016/j.esmoop.2023.101618.

33.王路润. ERG、D2-40、CD31、CD34在常见血管源性肿瘤的表达及其诊断意义[D]. 福州: 福建医科大学, 2018. [Wang  LR. Expression of ERG、D2-40、CD31、CD34 in patients with common angiogenic tumor[D]. Fuzhou: Fujian Medical University, 2018.] DOI: 10.7666/d.D01580443.